TitleInsight into the Interaction of L. Specialized Metabolites and Gastrointestinal Bitter Taste Receptors: Study in STC-1 Cells and Molecular Docking.
Publication TypeJournal Article
Year of Publication2024
AuthorsLela L, Ponticelli M, Carlucci V, Stevens JF, Faraone I, Tzvetkov NT, Milella L
JournalJ Nat Prod
Volume87
Issue8
Pagination2021-2033
Date Published2024 Aug 23
ISSN1520-6025
KeywordsAnimals, Cell Line, Cholecystokinin, Flavonoids, Gastrointestinal Tract, Glucagon-Like Peptide 1, Humans, Humulus, Mice, Molecular Docking Simulation, Molecular Structure, Propiophenones, Receptors, G-Protein-Coupled
Abstract

Bitter taste receptors, also known as taste 2 receptors (T2R), are expressed throughout the body and are involved in regulating different physiological processes. T2R expression in the intestinal tract regulates orexigenic and anorexigenic peptide secretion, thus becoming potential a potential target for controlling food intake and the prevalence of obesity and overweight. The present study aims to investigate the implication of hop bitter compounds such as α-acids, β-acids, and xanthohumol in the secretion of anorexigenic hormones and T2R expression in intestinal STC-1 cells. The tested bitter compounds induced the secretion of the anorexigenic hormones glucagon-like peptide 1 and cholecystokinin concurrently with a selective increase of murine expression. Xanthohumol and α-acids selectively increase 138 and 130-138 expression, respectively, in STC-1 cells, while β-acids increased the expression of all bitter receptors studied, including 119, 105, 138, 120, and 130. Increased intracellular calcium levels confirmed this activity. As all investigated bitter molecules increased 138 expression, computational studies were performed on 138 and its human orthologue T2R38 for the first time. Molecular docking experiments showed that all molecules might be able to bind both bitter receptors, providing an excellent basis for applying hop bitter molecules as lead compounds to further design gastrointestinal-permeable T2R agonists.

DOI10.1021/acs.jnatprod.4c00532
Alternate JournalJ Nat Prod
PubMed ID39126694
Grant ListS10 RR027878 / RR / NCRR NIH HHS / United States